– Reports Positive Preliminary Top-line Data from Second Rabbitpox Study – – Type C Meeting Requested with FDA Regarding Virologic Endpoint – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , March 05, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing
DURHAM, N.C. , March 04, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that Timothy Trost , Chief Financial Officer of Chimerix, will present at the Cowen and Company 39th Annual
DURHAM, N.C. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Tuesday, March 5, 2019 at 8:30 a.m.
Decreased HHV-6 Reactivation Observed Among Oral Brincidofovir Allogeneic Hematopoietic Cell Transplantation Recipients Results to be Presented at Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR 2019 DURHAM, N.C. , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a
M. Michelle Berrey to Step Down as Chief Executive Officer DURHAM, N.C. , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M.
DURHAM, N.C. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at
- Conference Call at 8:30 a.m. ET Today - DURHAM, N.C. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today reported financial results and provided a corporate update for the third
DURHAM, N.C. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey , M.D., M.P.H., Chief Executive Officer and Tim Trost, Chief Financial
DURHAM, N.C. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Thursday, November 8, 2018 at 8:30 a.m.
Data supports further clinical evaluation of brincidofovir for the treatment and prevention of BK virus DURHAM, N.C. , Oct. 27, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced data from two preclinical studies which assessed the in vivo antiviral activity of brincidofovir (BCV)
